uniQure NV 2022 SR
The report is uniQure's inaugural corporate responsibility report for 2022, highlighting the company's commitment to transforming lives through gene therapy. Key achievements include the approval of HEMGENIX and the establishment of an ESG committee to oversee priorities like community outreach, diversity, and environmental impact. The company reports a global workforce representing over 50 countries, with 54% female employees and a strong focus on employee wellness. Environmental initiatives focus on energy conservation and waste reduction at their facilities in the US and Europe.
Company: uniQure NV
Sector: Health Care
Country: Netherlands
Year: 2022
Type: SR
Pages: 11
Back to company
uniQure NV
Corporate Responsibility Report
The report is uniQure's inaugural corporate responsibility report for 2022, highlighting the company's commitment to transforming lives through gene therapy. Key achievements include the approval of HEMGENIX and the establishment of an ESG committee to oversee priorities like community outreach, diversity, and environmental impact. The company reports a global workforce representing over 50 countries, with 54% female employees and a strong focus on employee wellness. Environmental initiatives focus on energy conservation and waste reduction at their facilities in the US and Europe.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees